The new director at the FDA overseeing medical devices will confront criticisms about hasty approvals as she ushers in ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

The media has boiled down Project 2025’s main objectives affecting the public, but lacks the space to use direct quotes ...

Trump’s promises to overhaul health agencies with RFK met with some optimism and widespread expert dismay - Trump has ...

Managing stress and maintaining overall health can be quite challenging in today’s fast-paced world. Many people turn to ...

Sure, condoms are still an effective strategy for lowering the risk of sexually transmitted infections (STIs) — but now, they ...

His mission: "to transform our nation's food ... On X, he wrote: "If you work for the FDA and are part of this corrupt system ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

OrganOx Ltd., a medical technology company developing innovative solutions for organ preservation, and eGenesis, Inc., a ...

Cash Position: Cash, cash equivalents, and marketable securities were $463.3 million as of September 30, 2024, compared to $322.0 million as of December 31, 2023. Erasca expects its current cash, cash ...